Image credit: shutterstock
BostonGene, a leading provider of artificial intelligence (AI)-based molecular and immune profiling solutions, NEC Corporation, a leader in IT, network and AI technologies, and Japan Industrial Partners, a leading Tokyo-based private equity firm, have announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture aimed at advancing personalised medicine and dramatically improving patient outcomes.
The new company will utilise BostonGene's high-complexity molecular technology and advanced biocomputational algorithms, including BostonGene Tumor Portrait tests, to accelerate the development and validation of novel precision medicine approaches.
BostonGene's AI-powered cloud-based solutions, bioinformatics capabilities, analytical tools, and advanced next-generation molecular and immune profiling provide a comprehensive view of a cancer patient at a molecular level and identify actionable targets to make evidence-based treatment decisions. In addition, BostonGene uses its solution platform to provide a broad range of services for biopharma customers, including biomarker discovery, clinical trial testing, assay design and development, and companion diagnostics.
By equipping cancer care centres with BostonGene solutions, a greater number of patients will be able to benefit from genomic testing and personalised treatments. Furthermore, by utilising BostonGene industry solutions, Japanese researchers and biopharma companies will benefit from biomarker-driven therapy development.
